Málstofa Lífvísindaseturs - Novel Peptide-Drug Conjugate Melphalan Flufenamide

Læknagarður
stofa 201
Málstofa Lífvísindaseturs föstudaginn 3. september kl. 12:00 í Læknagarði stofu 201
Fyrirlesari: Dr. Ana Slipicevic, Oncopeptides AB, Sweden
Titill: Novel Peptide-Drug Conjugate Melphalan Flufenamide - A story of a successful industry-academia collaboration
Zoom link: https://eu01web.zoom.us/j/67319859829
Starfsferill: Ana Slipicevic Ph.D. Translational research Director at Oncopeptides AB. She is responsible for the preclinical development of lead compounds and the implementation of translational research strategies in early clinical development. Before joining Oncopeptides AB, she was principal investigator in vivo pharmacology at Medivir AS as well as a researcher at the Department of Pathology, Oslo University Hospital, where she was leading a research group focusing on basic biology and therapy of melanoma.
Dr. Ana Slipicevic, Oncopeptides AB, Sweden
